ClinicalTrials.gg
Status unknownNCT01913847Updated Nov 27, 2017

Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension

A Phase 3 interventional study of Sildenafil and Placebo in Pulmonary Hypertension and Systolic Dysfunction, sponsored by Hanmi Pharmaceutical Company Limited. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-11-27.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies testing sildenafil in Hypertension, Pulmonary — 1 open to participants now, 1 under way, none of them phase 3. sildenafil · Hypertension, Pulmonary.

Planned enrollment
7th of 50
144 · median 30
Started
2013
with 1 other
Phase 3
15 of 51
none open now
Registered
36th of 51
by date

Among the 51 studies testing sildenafil in Hypertension, Pulmonary, this one is the 7th largest by planned enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2013, is one of 15 in phase 3, and was the 36th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

1 of the 51 studies testing sildenafil in Hypertension, Pulmonary is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 99 (61%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing sildenafil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety and clinical efficacy of HGP1207 (Sildenafil) in subjects with pulmonary hypertension associated with systolic heart failure.

03

Conditions studied

  • Pulmonary Hypertension
  • Systolic Dysfunction
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of chronic heart failure ( Class II and III)
  • ≤ 40%
  • Elevated systolic PAP: ≥ 40 mmHg
  • Patients must be treated with an ACE inhibitor, ARB, beta-blocker, aldosterone antagonist at a stable dose for at least 4 weeks prior to visit 1

Exclusion criteria

Exclusion Criteria:

  • Patients with pulmonary hypertension associated with , interstitial lung disease, chronic thromboembolism or unclear/multifactorial mechanisms
  • Patients who have received Nitrates/NO donor or Cytochrome P450 3A4 inhibitors within 30 days prior to visit 1
  • Patients who have received calcium channel blocker, endothelin receptor antagonist, prostacyclin analogues, phosphodiesterase 5 inhibitors within 90 days prior to visit 1
  • History of or allergy to sildenafil or any of its formulation
  • Patients with hypertension (sitSBP >170 mmHg or sitDBP>100 mmHg) or hypotension (sitSBP\<90 mmHg or sitDBP\<50 mmHg)
  • Patients with other medical condition (i.e.,alcoholism, drug abuse) that may cause the patient to be non-compliant with the protocol, confound the data interpretation
  • Pregnant females or those of child bearing potential who have not had a negative pregnancy test
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Sildenafil

    Sildenafil 20 mg

    Drug: Sildenafil

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • Oral sildenafil 20 mg TID for 12 weeks

    Also known as: HGP1207, PAHTENSION chewable tablet

  • DrugPlacebo

    Oral placebo TID for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline in 6-min-walk test distance

    Time frame: at 12 weeks

Secondary outcomes

  1. Change from baseline in 6-min-walk test distance

    Time frame: at 6 weeks

  2. Change from baseline in systolic pulmonary arterial pressure (PAP)

    Time frame: at 6 weeks and 12 weeks

  3. Change from baseline in [NT pro-BNP]

    Time frame: at 6 weeks and 12 weeks

  4. Improvement in NYHA functional class

    Time frame: at 6 weeks and 12 weeks

  5. Quality of life (QoL) assessed by EuroQoL(EQ-5D-3L) and EQ visual analogue scales (VAS)

    Time frame: at 6 weeks and 12 weeks

  6. Delaying time to first occurrence of either cardiovascular events

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • 11 institutions including Hallym University Dongtan Sacred Heart Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Ok · Contactsokei@hanmail.net · 82-31-8086-2538
    • Kyu Hyung Ryu, M.D. Ph.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Dec 2018 and a completion of Dec 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2013
First posted
Aug 1, 2013
Start
Sep 2013
Primary completionEst.
Dec 2018
CompletionEst.
Dec 2018
Last update
Nov 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01913847
Responsible party
Sponsor
First posted
Aug 1, 2013
Start date
Sep 2013
Primary completion
Dec 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Nov 27, 2017

Study contacts

Kyu Hyung Ryu, M.D. Ph.D.
principal investigator · Hallym University Dongtan Sacred Heart Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion